IN2015KN00492A - - Google Patents

Info

Publication number
IN2015KN00492A
IN2015KN00492A IN492KON2015A IN2015KN00492A IN 2015KN00492 A IN2015KN00492 A IN 2015KN00492A IN 492KON2015 A IN492KON2015 A IN 492KON2015A IN 2015KN00492 A IN2015KN00492 A IN 2015KN00492A
Authority
IN
India
Prior art keywords
compounds
diseases
conditions
diabetes
infection
Prior art date
Application number
Other languages
English (en)
Inventor
Benjamin Jason Compton
Colin Malcolm Hayman
Ian Francis Hermans
David Samuel Larsen
Gavin Frank Painter
Regan James Anderson
Original Assignee
Callaghan Innovation Res Ltd
Benjamin Jason Compton
Colin Malcolm Hayman
Ian Francis Hermans
David Samuel Larsen
Gavin Frank Painter
Regan James Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Callaghan Innovation Res Ltd, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Regan James Anderson filed Critical Callaghan Innovation Res Ltd
Publication of IN2015KN00492A publication Critical patent/IN2015KN00492A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN492KON2015 2012-07-26 2013-07-26 IN2015KN00492A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ60147312 2012-07-26
PCT/NZ2013/000133 WO2014017928A1 (fr) 2012-07-26 2013-07-26 Composés organiques

Publications (1)

Publication Number Publication Date
IN2015KN00492A true IN2015KN00492A (fr) 2015-07-17

Family

ID=49997620

Family Applications (1)

Application Number Title Priority Date Filing Date
IN492KON2015 IN2015KN00492A (fr) 2012-07-26 2013-07-26

Country Status (9)

Country Link
US (1) US9586985B2 (fr)
EP (1) EP2877481B1 (fr)
JP (1) JP6528029B2 (fr)
KR (1) KR102162619B1 (fr)
CN (1) CN104736550B (fr)
AU (1) AU2013293646B2 (fr)
CA (1) CA2880191C (fr)
IN (1) IN2015KN00492A (fr)
WO (1) WO2014017928A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
WO2014200363A1 (fr) * 2013-06-10 2014-12-18 Victoria Link Limited Analogues de sphingoglycolipides
WO2015187040A1 (fr) * 2014-06-05 2015-12-10 Regan James Anderson Analogues d'amino-sphingoglycolipide
JP6453033B2 (ja) * 2014-10-22 2019-01-16 国立大学法人北海道大学 糖スフィンゴシン及びスフィンゴ塩基の製造方法
US9394312B1 (en) * 2015-06-14 2016-07-19 Mark Quang Nguyen Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
WO2017083830A1 (fr) * 2015-11-13 2017-05-18 La Jolla Institute For Allergy And Immunology Composés de sphingamide et procédés de liaison de cellules inkt
US10919926B2 (en) 2016-03-22 2021-02-16 Keio University Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition
WO2019122050A1 (fr) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Méthodes de traitement
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
AU2003225891A1 (en) * 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
JP3824319B2 (ja) 2004-02-19 2006-09-20 株式会社紀文フードケミファ 抗ウイルス作用組成物
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
US7772380B2 (en) * 2004-08-27 2010-08-10 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
WO2007035717A2 (fr) * 2005-09-19 2007-03-29 The Rockefeller University Glycolipides et leurs analogues antigenes des cellules nk t
WO2008047174A1 (fr) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Analogues de l'alpha-galactocéramide, leurs procédés de fabrication, composés intermédiaires utiles dans ces procédés, et compositions pharmaceutiques les contenant
US20080133801A1 (en) * 2006-12-04 2008-06-05 Aten International Co., Ltd. Keyboard-video-mouse switch system for switching between computers having a plurality of video sources each and switching method thereof
EP2698353B1 (fr) 2007-04-12 2024-02-07 Novozymes Biologicals, Inc. Traitement des eaux usées utilisant des souches microbiennes
EP2058011A1 (fr) * 2007-11-07 2009-05-13 Wittycell Cellule Nkt activant des antigènes et/ou médicaments à liaison gycolipids covalentyl
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物

Also Published As

Publication number Publication date
AU2013293646B2 (en) 2017-10-19
CN104736550B (zh) 2017-12-29
JP6528029B2 (ja) 2019-06-12
KR20150073942A (ko) 2015-07-01
KR102162619B1 (ko) 2020-10-08
CN104736550A (zh) 2015-06-24
JP2015522656A (ja) 2015-08-06
EP2877481A4 (fr) 2016-04-06
CA2880191A1 (fr) 2014-01-30
EP2877481A1 (fr) 2015-06-03
EP2877481B1 (fr) 2019-11-27
CA2880191C (fr) 2021-04-20
AU2013293646A1 (en) 2015-03-12
WO2014017928A1 (fr) 2014-01-30
US9586985B2 (en) 2017-03-07
US20150191503A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
IN2015KN00492A (fr)
AU2018236800B2 (en) DNA-PK inhibitors
NZ708727A (en) Conjugate compounds
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MD20150091A2 (ro) Compuşi antivirali
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
TW201613901A (en) New compounds
WO2015085318A3 (fr) Vaccins adaptatifs ciblés
NZ700928A (en) Dna-pk inhibitors
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MY165579A (en) Synthetic methods for spiro-oxindole compounds
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
WO2013120022A3 (fr) Traitement de l'hypoglycémie
PH12014502032A1 (en) Treatment of brain cancer
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2014086453A8 (fr) Composés azahétérobicycliques
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
IN2013MU03118A (fr)
PH12017501872A1 (en) Methods of treating diseases
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs